Apigenin modulates GABAergic and glutamatergic transmission in cultured cortical neurons.
Level 5 - mechanism / opinion, no new human data
In vitro electrophysiological and cell culture study
PubMed 15464088 · doi:10.1016/j.ejphar.2004.08.043
What was done
Researchers used patch-clamp electrophysiology to examine how apigenin modulates GABAergic and glutamatergic neurotransmission. Recombinant alpha1beta2gamma2 GABA_A receptors expressed in HEK293 cells and primary cultured cortical neurons were assessed for receptor-mediated currents, spontaneous inhibitory postsynaptic currents (sIPSCs), and spontaneous excitatory postsynaptic currents (sEPSCs). The effects of apigenin on AMPA- and NMDA-mediated currents, as well as neuroprotection against glutamate-induced toxicity in cultured cortical and cerebellar neurons, were also evaluated.
What was found
Apigenin reversibly decreased GABA-evoked currents in HEK293 cells and reduced both the amplitude and frequency of GABA_A-mediated sIPSCs in cultured cortical neurons. It was largely inactive on AMPA-mediated currents but inhibited NMDA receptor-mediated responses with a half-maximal inhibitory concentration (IC50) of 10 µM. Apigenin also decreased the peak amplitude and frequency of sEPSCs and protected cultured cerebellar and cortical neurons from glutamate neurotoxicity. Beyond the IC50 value, no exact quantitative figures or confidence intervals were reported in the abstract.
Why it matters
This study identifies NMDA receptor antagonism as a novel cellular target for apigenin. This mechanism offers a plausible explanation for its sedative and neuroprotective properties observed in preclinical models.
Limits
The study is restricted to in vitro and cell-culture preparations and does not establish whether apigenin achieves brain concentrations sufficient to inhibit NMDA receptors in vivo. The abstract omits sample sizes, replication counts, and precise quantitative measurements for several electrophysiological endpoints.
Cited by
- partial Apigenin and chamomile act to quiet or downregulate frontal cortex activity to facilitate sleep onset.